Breakthrough Type 1 Diabetes Onset Prevention Therapy on the Horizon
Studies show that new prevention therapy are near.
Good news is expected for preventing the onset of type1 diabetes (T1D), a disease that impacts over 1.6 million Americans, including 200,000 youth under the age of 20. T1D is an autoimmune disease caused by the destruction of beta cells in the pancreas typically taking more than a decade off a person's life with life expectancy reduced by 16 years on average for people diagnosed before the age of 10.
An investigational anti-CD3 monoclonal antibody (mAb) called Teplizumab is being developed for the delay of T1D in at-risk individuals, by resetting a patient’s immune system. This single course therapy administered via a two-week period of 30-minute daily infusions is currently scheduled to be reviewed by the FDA on November 17, 2022.
Teplizumab has been shown to delay progression to clinical T1D by a median of almost 3 years and could be a very impactful breakthrough therapy for patients at risk or recently diagnosed with T1D. If approved, Teplizumab would be the first pharmaceutical therapy that could delay the onset of T1D and one of the most significant diabetes treatment developments in recent years.
To read more about the highly anticipated diabetes prevention therapy, Click Here.